Correct - it commenced just after Imugene acquired the license to Azer-cel (see page 3-4 of the company's half year report ending Dec 2023). Preliminary data from these trials are expected in H2 2024.Preliminary data from a Phase 1b trial is typically released at an interim point during the trial when enough data has been gathered to provide early insights, but before the trial is fully complete. This interim data helps stakeholders understand the drug’s potential and guides future research and development decisions. However, I must admit the presentation that Dr Shah gave at iwCAR-T 2024 seemed a little concerning
Why IMU is a multi multi bagger, page-25214
-
- There are more pages in this discussion • 1,620 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.0¢ |
Change
0.001(2.04%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.8¢ | $262.8K | 5.378M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 700408 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 5672796 | 18 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |